Stockreport

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RenovoRx, Inc.  (RNXT) 
PDF Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Onc [Read more]